How lung cancer affects immune responses to COVID-19
Vulnerability of SARS- CoV-2 Infection in Lung Cancer Based on Serological Antibody Analyses
This study is looking at how people with lung cancer react to COVID-19 infections and vaccines, checking how well their immune systems work and what that means for their health over time.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11160900 on NIH RePORTER |
What this research studies
This research investigates how patients with lung cancer respond to COVID-19 infections and vaccinations. It focuses on understanding the immune responses of these patients, particularly how effective their immune systems are against the virus and its variants. The study collects blood samples to analyze antibody responses and other biological factors that may influence susceptibility to COVID-19. Additionally, it examines the long-term health effects of COVID-19 on lung cancer patients and the impact of different vaccination strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with lung cancer who are concerned about their vulnerability to COVID-19.
Not a fit: Patients without lung cancer or those who are not currently undergoing treatment for lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved vaccination strategies and better management of COVID-19 in lung cancer patients.
How similar studies have performed: Previous research has shown that understanding immune responses in cancer patients can lead to better treatment outcomes, suggesting this approach has potential for success.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Hirsch, Fred R — Icahn School of Medicine at Mount Sinai
- Study coordinator: Hirsch, Fred R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.